Publications
Detailed Information
Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min J. | - |
dc.contributor.author | Lee, Sun-Kyung | - |
dc.contributor.author | Oh, Sohee | - |
dc.contributor.author | Kim, Hyoun-Ah | - |
dc.contributor.author | Park, Yong-Beom | - |
dc.contributor.author | Lee, Shin-Seok | - |
dc.contributor.author | Shin, Kichul | - |
dc.date.accessioned | 2022-06-21T08:01:00Z | - |
dc.date.available | 2022-06-21T08:01:00Z | - |
dc.date.issued | 2022-06-18 | - |
dc.identifier.uri | https://doi.org/10.1007/s40744-022-00467-4 | - |
dc.identifier.uri | https://hdl.handle.net/10371/182627 | - |
dc.description.abstract | Abstract
Introduction To compare the efficacy of abatacept and tumor necrosis factor inhibitor (TNFi) in patients with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) and identify those who benefit most from abatacept over TNFi. Methods This observational study identified RA patients who were ACPA-positive and initiated abatacept or TNFi from the Korean College of Rheumatology Biologics and Targeted therapy registry. Propensity score (PS) matching was performed to balance baseline confounding in abatacept- or TNFi-treated patients. The major endpoints were changes in Clinical Disease Activity Index (CDAI) and achievement of CDAI remission/low disease activity after 1year of treatment. Subgroup analysis was mainly performed stratified by prior biologics use. Results A total of 291 PS-matched, ACPA-positive RA patients who initiated abatacept (n = 97) and TNFi (n = 194) were included. From baseline CDAI scores of 26.52 in the abatacept group and 26.38 in the TNFi group, the mean changes after 1year were − 16.78 and − 13.61, respectively (difference − 3.17, p = 0.020). The proportion of patients achieving CDAI remission/low disease activity was 68.0% with abatacept and 52.6% with TNFi (p = 0.013). In the subgroup analysis, patients that were biologics-naïve had better improvement in CDAI after treatment with abatacept than TNFi (difference −3.35, p = 0.021). Conclusions This real-world study suggests that abatacept may have better clinical response compared to TNFi in patients with established ACPA-positive RA, especially in those that were biologics-naïve. | - |
dc.title | Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry | - |
dc.type | Journal Article | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2022-06-19T03:14:34Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.